tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M

Expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, will fund its planned operations into early Q1 2026.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1